News & Analysis as of

Life Sciences Obesity

Dentons

Ep. 4 - Ozempic, Wegovy, and the New Compliance Risks for Providers

Dentons on

Diabetes and obesity drugs have skyrocketed in popularity as of late. According to a report released by Trilliant Health in September 2023, healthcare providers in the United States wrote more than 9 million prescriptions for...more

Maynard Nexsen

Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 179: Obesity Effects on the Workforce & Economy with Tim...

Maynard Nexsen on

Recorded at SCBIO’s 2024 annual meeting, hosts Heather and Lauren welcome healthcare economist and GlobalData Director Tim Dall, who has studied the economic burden of chronic disease for over 25 years. The group discusses...more

McDonnell Boehnen Hulbert & Berghoff LLP

Guest Post -- The Emergent Microbiome: A Revolution for the Life Sciences – Part III, Obesity and other Metabolic Disorders

The gut microbiome, a collection of microbes living in the gastrointestinal tract, has emerged as an attractive target for pharmaceutical intervention for the treatment of a variety of disorders. This is the fourth article...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide